NDA 050580 · Labs Delbert
Azactam
Aztreonam · Injection · Monobactam Antibacterial
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Dec 31, 1986
Approved uses
2
Original approval plus efficacy supplements
Registered trials
66
34 Phase 3, 9 recruiting
FAERS reports
2,727
2,510 serious, 590 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of AZACTAM (aztreonam for injection, USP) and other antibacterial drugs, AZACTAM should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. AZACTAM is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , Enterobacter cloacae , Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Haemophilus influenzae , Proteus mirabilis , Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli , Klebsiella pneumoniae , Pseudomonas aeruginosa , Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli , Proteus mirabilis , Serratia marcescens , Enterobacter species, Pseudomonas aeruginosa , Klebsiella pneumoniae , and Citrobacter species*. Intra-abdominal Infections , including peritonitis caused by Escherichia coli , Klebsiella species including K....
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 1, 1996 Supplement 8 · Efficacy
- Dec 31, 1986 Original approval · Type 1 - New Molecular Entity · priority review Review
3 products under this application
- AZACTAM · AZTREONAM 1GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- AZACTAM · AZTREONAM 2GM/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- AZACTAM · AZTREONAM 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Aztreonam" as an intervention, any sponsor and status, largest first.
- Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT01984684 · 850 participants · Start May 2014 · Primary completion Dec 2015
Drug: delafloxacin; vancomycin and 1 more · For: Skin and Subcutaneous Tissue Bacterial Infections; Skin Structures and Soft Tissue Infections
Sites: Mobile, Alabama; Montgomery, Alabama; Anaheim, California · 94 sites in all
- Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin InfectionsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01499277 · 802 participants · Start May 2012 · Primary completion Jun 2014
Drug: Ceftaroline fosamil; Vancomycin and 1 more · For: Complicated Skin and Soft Tissue Infection
Sites: Chula Vista, California; Orlando, Florida; West Palm Beach, Florida · 91 sites in all
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00424190 · 698 participants · Start Feb 2007 · Primary completion Nov 2007
Drug: IV Vancomycin plus IV Aztreonam; Ceftaroline · For: Bacterial Infections
Sites: Dothan, Alabama; Long Beach, California; Los Angeles, California · 52 sites in all
- Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin InfectionsPivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00423657 · 680 participants · Start Mar 2007 · Primary completion Dec 2007
Drug: ceftaroline; vancomycin plus aztreonam and 1 more · For: Bacterial Infections
Sites: Buena Park, California; Hawaiian Gardens, California; Los Angeles, California · 54 sites in all
- Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT03137173 · 679 participants · Start Feb 19, 2018 · Primary completion Apr 22, 2019
Drug: ceftobiprole medocaril; vancomycin+aztreonam · For: Acute Bacterial Skin and Skin Structure Infections
Sites: Anaheim, California; Chula Vista, California; Fresno, California · 34 sites in all
- Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure InfectionsPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT01811732 · 660 participants · Start Apr 2013 · Primary completion Jul 2014
Drug: Delafloxacin; Vancomycin and 2 more · For: Skin and Subcutaneous Tissue Bacterial Infections
Sites: Montgomery, Alabama; Anaheim, California; Chula Vista, California · 50 sites in all
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
- A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With AppendicitisStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT03380793 · 614 participants (planned) · Start Sep 2016 · Primary completion Oct 2018
Drug: morinidazole · For: Appendicitis
Sites: Beijing, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use194
- pyrexia176
- eosinophilia160
- drug ineffective152
- dyspnoea134
- rash131
- acute kidney injury127
- drug reaction with eosinophilia and systemic symptoms120
- thrombocytopenia117
- septic shock103
- condition aggravated101
- renal failure98
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 42 |
| 2005 | 46 |
| 2006 | 51 |
| 2007 | 37 |
| 2008 | 47 |
| 2009 | 50 |
| 2010 | 50 |
| 2011 | 85 |
| 2012 | 78 |
| 2013 | 75 |
| 2014 | 124 |
| 2015 | 104 |
| 2016 | 148 |
| 2017 | 139 |
| 2018 | 158 |
| 2019 | 206 |
| 2020 | 207 |
| 2021 | 264 |
| 2022 | 161 |
| 2023 | 183 |
| 2024 | 215 |
| 2025 | 149 |
| 2026 | 108 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azactam (Aztreonam)
2024 spending
$107K
Beneficiaries
133
255 claims
Per beneficiary
$803
$6.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $309,078 |
| 2021 | $338,839 |
| 2022 | $218,231 |
| 2023 | $207,452 |
| 2024 | $106,778 |
Part B: Azactam* (Aztreonam*) · HCPCS J0457
2024 spending
$117K
Beneficiaries
981
1,752 claims
Per beneficiary
$119
2024 ASP limit $2.30 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $13,640 |
| 2024 | $116,665 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.
Carmeli Y, Cisneros JM, Paul M, et al. · Lancet Infect Dis 2025 · Clinical Trial, Phase III, Comparative Study
- Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.
Holland TL, Cosgrove SE, Doernberg SB, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Equivalence Trial
- Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients.
Xie R, Rogers H, Chow JW, et al. · Antimicrob Agents Chemother 2025 · Clinical Trial, Phase III, Multicenter Study
- Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis.
Gupta N, Boodman C, Prayag P, et al. · Expert Rev Anti Infect Ther 2024 · Systematic Review, Meta-Analysis
- Aztreonam--an overview.
Hopefl AW · Drug Intell Clin Pharm 1985 · Clinical Trial, Review
- Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.
Quittner AL, O'Donnell AE, Salathe MA, et al. · Thorax 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Labs Delbert
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.